Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV005094209 | SCV005756620 | pathogenic | not provided | 2024-06-07 | criteria provided, single submitter | clinical testing | This sequence change replaces glycine, which is neutral and non-polar, with alanine, which is neutral and non-polar, at codon 347 of the KCNQ5 protein (p.Gly347Ala). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with developmental and epileptic encephalopathy (PMID: 35377796). In at least one individual the variant was observed to be de novo. ClinVar contains an entry for this variant (Variation ID: 975567). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt KCNQ5 protein function with a positive predictive value of 80%. Experimental studies have shown that this missense change affects KCNQ5 function (PMID: 35377796). This variant disrupts the p.Gly347 amino acid residue in KCNQ5. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 35377796). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. |
| Centre de Biologie Pathologie Génétique, |
RCV001252273 | SCV001428025 | likely pathogenic | Intellectual disability, autosomal dominant 46 | 2019-01-01 | no assertion criteria provided | clinical testing |